Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024.

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...

Pharmaceutical stocks can bring an element of safety to your portfolio. All of this equals a rather steady stream of revenue ...

As a result of the disappointing results, Boehringer said that it was abandoning a long-term extension trial called CONNEX-X, ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...